Ocular Therapeutix (OCUL) Change in Receivables (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Change in Receivables of $5.9 million for Q2 2026, up 13.93% year-over-year from $5.2 million in Q2 2025, and up 193.83% on a QoQ basis from -$6.3 million in Q1 2026.
Ocular Therapeutix (OCUL) Change in Receivables (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Change in Receivables for 14 years, with the latest figure at $5.9 million in Q2 2026.
- Change in Receivables for Q2 2026 came in at $5.9 million, up 13.93% year-over-year; the trailing twelve-month figure through Jun 2026 was -$151000.0 (down 183.89% YoY), and the FY2025 annual result was -$1.7 million, down 127.99% from the prior year.
- Change in Receivables improved to $5.9 million in Q2 2026, from -$6.3 million in the prior quarter.
- Over five years, Change in Receivables peaked at $6.2 million in Q2 2023 and troughed at -$7.2 million in Q1 2025.
- A 5-year average of $507000.0 and a median of $361500.0 in 2024 frame the typical range for Change in Receivables.
- The largest YoY upside for Change in Receivables was 11766.67% in 2025 against a maximum downside of 2052.86% in 2025.
- A 5-year view of Change in Receivables shows it stood at $1.5 million in 2022, then soared by 70.06% to $2.6 million in 2023, then declined by 16.87% to $2.2 million in 2024, then slumped by 105.48% to -$118000.0 in 2025, then soared by 5111.86% to $5.9 million in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were $5.9 million in Q2 2026, -$6.3 million in Q1 2026, and -$118000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 5.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.91 Mn |
| Jun 30, 2026 | 5.91 Mn |
| Mar 31, 2026 | -6.30 Mn |
| Mar 31, 2026 | -6.30 Mn |
| Dec 31, 2025 | -118,000.00 |
| Dec 31, 2025 | -118,000.00 |
| Sep 30, 2025 | 356,000.00 |
| Sep 30, 2025 | 356,000.00 |
| Jun 30, 2025 | 5.19 Mn |
| Jun 30, 2025 | 5.19 Mn |
| Mar 31, 2025 | -7.17 Mn |
| Mar 31, 2025 | -7.17 Mn |
| Dec 31, 2024 | 2.15 Mn |
| Dec 31, 2024 | 2.15 Mn |
| Sep 30, 2024 | 3,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 3.69 Mn |
| Jun 30, 2024 | 3.69 Mn |
| Mar 31, 2024 | 367,000.00 |
| Mar 31, 2024 | 367,000.00 |